Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Benefit of Apremilast Treatment of Patients With Moderate-to-severe Psoriasis After Transition From Fumaric Acid Esters

NCT02954081 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02954081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02954081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Benefit of Apremilast Treatment of Patients With Moderate-to-severe Psoriasis After Transition From Fumaric Acid Esters
Lead sponsor
Amgen
Phase
Observational
Overall status
Completed
Start date
January 26, 2017
Completion date
August 15, 2022
Enrollment
687 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis